Stonepine Capital Reduces Indivior Stake by 250,000 Shares, Valuation Drops by $2.75 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 28 2025
0mins
Source: NASDAQ.COM
- Reduction Action: Stonepine Capital reduced its Indivior stake by 250,000 shares in Q3, leading to a valuation drop of approximately $2.75 million, indicating a cautious outlook on the company's future performance.
- Position Change: As of September 30, Stonepine held 100,000 shares of Indivior valued at $2.41 million, with its stake percentage decreasing from 5.06% to 1.96%, reflecting diminished confidence in the stock.
- Performance Metrics: Indivior reported $314 million in revenue for Q3, with SUBLOCADE sales increasing 15% year-over-year to $219 million, driving a 14% rise in adjusted EBITDA to $120 million, showcasing improved operational momentum.
- Future Guidance: Indivior's management raised its full-year 2025 revenue guidance sharply to $1.18 billion to $1.22 billion and plans to save at least $150 million in annual operating expenses starting next year, demonstrating a strategic commitment to cost discipline and sustained growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INDV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INDV
Wall Street analysts forecast INDV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INDV is 38.00 USD with a low forecast of 35.00 USD and a high forecast of 41.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 35.380
Low
35.00
Averages
38.00
High
41.00
Current: 35.380
Low
35.00
Averages
38.00
High
41.00
About INDV
Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kevin Mahn Advises Investors to Focus on Long-Term Growth Amid Market Volatility
- Market Volatility Impact: Kevin Mahn highlighted that in 2025, markets initially fell nearly 15% due to tariff fears, but those who remained invested saw a 39% rebound by year-end, underscoring the risks of reacting to short-term headlines.
- Identifying Investment Opportunities: Mahn advised investors to focus on long-term growth, particularly the AI boom, with trillions expected in infrastructure investments by 2030, emphasizing the potential of companies supporting this growth, such as data center cooling and power providers.
- Stability and Yield: He mentioned Comfort Systems USA Inc., recently added to the S&P 500, and Duke Energy Corp., trading at 17X forward earnings with a 3.7% dividend yield, as solid choices for stability in turbulent markets.
- Sector Outlook: Mahn also pointed out promising sectors like aerospace and defense, driven by rising global military budgets, and small-cap biotech, benefiting from patent cliffs and M&A activity, recommending companies like L3 Harris and Indivior as investment targets.
Continue Reading
Healthcare Sector Outperforms S&P 500 with 12.52% Gain and 3.20 Health Score
- Sector Performance: The S&P 500 healthcare sector achieved a 12.52% gain in 2025, lagging behind the broader S&P 500 index's 16.39% increase, indicating relative strength within the healthcare industry.
- Health Score Analysis: Seeking Alpha's Quant Ratings assign an average health score of 3.20 out of 5 to the healthcare sector, based on 261 stocks with market capitalizations above $2 billion, reflecting a generally healthy outlook for the sector.
- Stock Rating Distribution: Among the 261 stocks, 37 are rated Buy or higher, 213 are Neutral, and 11 are Strong Sell, showcasing varied market perceptions and investment opportunities within the healthcare sector.
- Top Stock Ratings: Ahead of the upcoming earnings season, stocks like Grail (GRAL) and Indivior PLC (INDV) received strong buy ratings of 4.97 and 4.95, respectively, indicating strong investor confidence in these companies.
Continue Reading